CA3027546A1 - Engineered treg cells - Google Patents

Engineered treg cells Download PDF

Info

Publication number
CA3027546A1
CA3027546A1 CA3027546A CA3027546A CA3027546A1 CA 3027546 A1 CA3027546 A1 CA 3027546A1 CA 3027546 A CA3027546 A CA 3027546A CA 3027546 A CA3027546 A CA 3027546A CA 3027546 A1 CA3027546 A1 CA 3027546A1
Authority
CA
Canada
Prior art keywords
cell
cells
regulatory
engineered
treg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3027546A
Other languages
English (en)
French (fr)
Inventor
Alexander Y. RUDENSKY
Takatoshi CHINEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CA3027546A1 publication Critical patent/CA3027546A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
CA3027546A 2016-06-16 2017-06-15 Engineered treg cells Pending CA3027546A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662351104P 2016-06-16 2016-06-16
US62/351,104 2016-06-16
PCT/US2017/037794 WO2017218850A1 (en) 2016-06-16 2017-06-15 Engineered treg cells

Publications (1)

Publication Number Publication Date
CA3027546A1 true CA3027546A1 (en) 2017-12-21

Family

ID=60663377

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3027546A Pending CA3027546A1 (en) 2016-06-16 2017-06-15 Engineered treg cells

Country Status (8)

Country Link
US (1) US20190322983A1 (OSRAM)
EP (1) EP3472305A4 (OSRAM)
JP (2) JP2019518460A (OSRAM)
CN (1) CN109415698A (OSRAM)
AU (1) AU2017285319A1 (OSRAM)
CA (1) CA3027546A1 (OSRAM)
MA (1) MA45498A (OSRAM)
WO (1) WO2017218850A1 (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110022907A (zh) * 2016-10-10 2019-07-16 国家生物技术研究所公司 非细胞毒性的修饰细胞及其用途
GB201714718D0 (en) 2017-09-13 2017-10-25 Autolus Ltd Cell
WO2019178518A1 (en) * 2018-03-16 2019-09-19 The Regents Of The University Of California Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells
CN112955174A (zh) 2018-07-09 2021-06-11 旗舰先锋创新V股份有限公司 融合剂脂质体组合物和其用途
GB201814203D0 (en) * 2018-08-31 2018-10-17 King S College London Engineered regulatory t cell
AU2019378883A1 (en) 2018-11-14 2021-06-03 Flagship Pioneering Innovations V, Inc. Fusosome compositions for T cell delivery
AU2020215725A1 (en) * 2019-02-01 2021-09-23 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
US11160832B2 (en) * 2019-07-09 2021-11-02 The Children's Mercy Hospital Engineered regulatory T cells
WO2021154882A1 (en) * 2020-01-27 2021-08-05 H. Lee Moffitt Cancer Center And Research Institute Inc. Hdac6-inhibited human regulatory t cells
GB2609103A (en) * 2020-02-25 2023-01-25 Quell Therapeutics Ltd Chimeric receptors for use in engineered cells
GB202102637D0 (en) 2021-02-24 2021-04-07 Quell Therapeutics Ltd Engineered regulatory t cell
EP4403580A1 (en) 2023-01-23 2024-07-24 Medizinische Hochschule Hannover Anti-entpd3 chimeric antigen receptor
CN120981484A (zh) 2023-01-23 2025-11-18 汉诺威医学院 抗entpd3嵌合抗原受体
KR20250165594A (ko) 2023-02-07 2025-11-26 퀠 테라퓨틱스 리미티드 Treg 세포의 배양 방법
EP4420676A1 (en) 2023-02-24 2024-08-28 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024175805A1 (en) 2023-02-24 2024-08-29 Medizinische Hochschule Hannover Chimeric antigen receptor
CN120981564A (zh) 2023-03-17 2025-11-18 圭尔医疗有限公司 调节性t细胞疗法
EP4434539A1 (en) 2023-03-20 2024-09-25 Medizinische Hochschule Hannover Chimeric antigen receptor
WO2024194355A1 (en) 2023-03-20 2024-09-26 Medizinische Hochschule Hannover Chimeric antigen receptor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235873B1 (en) * 1999-07-31 2001-05-22 The Rockefeller University Constitutively active transcription factors and their uses for identifying modulators of activity including dysproliferative cellular changes
JP2010531138A (ja) * 2007-06-13 2010-09-24 ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー 制御性ｔ細胞ならびに同製造および使用方法
US8658159B2 (en) * 2008-06-30 2014-02-25 Versitech Limited Method to induce and expand therapeutic alloantigen-specific human regulatory T cells in large-scale
EP4166148A1 (en) * 2014-06-06 2023-04-19 Memorial Sloan-Kettering Cancer Center Mesothelin-targeted chimeric antigen receptors and uses thereof
AU2015276131A1 (en) * 2014-06-17 2016-11-17 Cellectis CD123 specific multi-chain chimeric antigen receptor
US11111505B2 (en) * 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof

Also Published As

Publication number Publication date
EP3472305A1 (en) 2019-04-24
JP2022058995A (ja) 2022-04-12
US20190322983A1 (en) 2019-10-24
CN109415698A (zh) 2019-03-01
JP2019518460A (ja) 2019-07-04
EP3472305A4 (en) 2020-01-15
MA45498A (fr) 2019-04-24
AU2017285319A1 (en) 2018-12-20
WO2017218850A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
US20190322983A1 (en) Engineered treg cells
Chinen et al. An essential role for the IL-2 receptor in Treg cell function
Yi et al. The adaptor TRAF3 restrains the lineage determination of thymic regulatory T cells by modulating signaling via the receptor for IL-2
US11786550B2 (en) gRNA targeting HPK1 and a method for editing HPK1 gene
Levine et al. Suppression of lethal autoimmunity by regulatory T cells with a single TCR specificity
Lelliott et al. NKG7 enhances CD8+ T cell synapse efficiency to limit inflammation
Wang et al. Natural killer T-cell agonist α-galactosylceramide and PD-1 blockade synergize to reduce tumor development in a preclinical model of colon cancer
Lee et al. The endogenous repertoire harbors self-reactive CD4+ T cell clones that adopt a follicular helper T cell-like phenotype at steady state
Umeshappa et al. Re-programming mouse liver-resident invariant natural killer T cells for suppressing hepatic and diabetogenic autoimmunity
Smith-Raska et al. The transcription factor Zfx regulates peripheral T cell self-renewal and proliferation
EP4048304A1 (en) Immunotherapy targeting tumor neoantigenic peptides
Russell et al. Lrp10 suppresses IL7R limiting CD8 T cell homeostatic expansion and anti-tumor immunity
Boardman et al. Armored human CAR Treg cells with PD1 promoter-driven IL-10 have enhanced suppressive function
US20190376030A1 (en) Regulatory t cell populations
Lee et al. RORα enforces stability of the T-helper-17 cell effector program
US20250041344A1 (en) Gene editing methods for modulating expression of id-3, an inhibitor of dna-binding transcription factors, thereby affecting t-cell function
Ojo Exploration of Exhausted CD8+ T Cell Subset Diversity During Chronic Viral Infection and Cancer: A Role for Gfi1
Fox Towards Gene Therapy for CTLA4 Insufficiency
Whitaker The Role of the AP-1 Transcription Factor JunB in the Maintenance and Function of Mature T Helper Cells
CA3076095C (en) A grna targeting hpk1 and a method for editing hpk1 gene
Jamison et al. An IL-2 mutein increases IL-10 and CTLA-4-dependent suppression of dendritic cells by regulatory T cells
Duhan et al. FcRγ-Dependent NK Cell Licensing through CD244 Promotes Antitumor Immunity
Kuchroo The role of PD-1 in modulating T cell responses in autoimmunity and cancer
Nixon Tissue-Resident Innate Immunity in Health and Cancer
Shen Reprogramming of Regulatory T cells in the Tumour Microenvironment

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220615

EEER Examination request

Effective date: 20220615

EEER Examination request

Effective date: 20220615

EEER Examination request

Effective date: 20220615